The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients
China recorded unprecedented improvement in its API manufacturing score in the 2022 end of year CPHI Survey
Brexit had a negative impact on NHS staff shortages and worsened the workforce crisis
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
The strategic appointment is also critical to reinforcing Healthium’s market leadership, corporate governance and deep domain expertis
Clinic will offer Comprehensive Genetic Counselling and Testing Services to empower patients with personalized care
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
Subscribe To Our Newsletter & Stay Updated
